Analyst Price Targets — ACB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 11, 2023 3:01 pm | EBITDA Q3 | Piper Sandler | $1.00 | $0.88 | Pulse 2.0 | Aurora Cannabis Stock Receives A $1 Price Target (ACB) |
| May 28, 2021 12:00 am | Heather Balsky | Bank of America Securities | $8.75 | $9.66 | StreetInsider | BofA Securities Reiterates Neutral Rating on Aurora Cannabis Inc. (ACB:CN) (ACB) |
| May 14, 2021 12:00 am | Tamy Chen | BMO Capital | $8.00 | $6.86 | TheFly | Aurora Cannabis upgraded to Market Perform from Underperform at BMO Capital |
Latest News for ACB
NASDAQ | TSX: ACB Q1 launches reinforce Aurora's medical‑first strategy, expanding access to high‑quality products across multiple formats Scaled launches across Canada, Europe and Australia support growing demand in regulated international medical markets Continued focus on quality, patient needs and reliable global supply through Aurora's extensive GMP‑certified network EDMONTON, AB, April 28, 2026 /PRNewswire/ -…
Aurora Cannabis Inc. has transformed into a cannabis-focused company with improving international revenue and margins, while spinning off its Bevo division. ACB's balance sheet now shows net cash of C$46.7 million, achieved through equity sales, and enterprise value trades at just 3.8x projected FY27 adjusted EBITDA. I target a 64% upside for ACB to US$5.58 within a year, based on a 6x FY28 adjusted EBITDA multiple,…
Markets don't usually wait for permission — they anticipate it.
NASDAQ | TSX: ACB EDMONTON, AB, April 15, 2026 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, is pleased to announce it has acquired Safari Flower Company, an established EU GMP certified cannabis cultivator and manufacturer. Aggregate consideration is valued at $26.5 million, subject to customary adjustments, and…
Aurora Cannabis stock has slid 19% YTD as competition and weak consumer cannabis weigh, but strong medical growth and rising margins could shape its next move.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for ACB.
Senate Trading
No Senate trades found for ACB.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.